Esther van den Pol

Health-related quality of life with first- vs tweedelijns CDK4/6 inhibitor use in gevorderd breast cancer: results fr...

Health economic outcomes and costs of CDK4/6 inhibitor use in first- versus tweedelijns for gevorderd breast cancer: ...